Biotage AB (Uppsala, Sweden) has agreed a deal to purchase all outstanding shares in Horizon Technology Inc. for $18.4 million.
Biotage AB (Uppsala, Sweden) has agreed a deal to purchase all outstanding shares in Horizon Technology Inc. for $18.4 million.
Based in New Hampshire, USA, Horizon Technology is a provider of separation systems and consumables in areas such as water purification, food safety, biofuels, agriculture, pharmaceuticals, and the petrochemical industry. The purchase of Horizon Technology will strengthen Biotage’s position within environmental applications and food safety and allow Biotage to offer a more comprehensive portfolio of products.
“The acquisition of Horizon is in line with our strategy to grow our separation business through expansion into new application areas,” said Torben Jörgensen, CEO of Biotage. “This transaction enables Horizon’s existing products to reach a larger global market through Biotage’s direct sales channels, at the same time as Biotage’s existing products get access to customers in industries where Biotage historically has not been as active.”
“We are excited to partner with Biotage for the next phase of Horizon’s development,” said Robert S. Johnson, co-founder and CEO of Horizon. “This combination will allow Horizon’s product offering to continue to expand its global footprint and open up new opportunities for developing and bringing our innovative products to the market,” he continued.
For more information, please visit: www.biotage.com
Determining Neurotransmitters in Spinal Cords with UHPLC
February 18th 2025Researchers at Jilin University (Changchun, China) developed a highly sensitive, rapid, and accurate method for analyzing neurotransmitters (NTs) in rat spinal cord tissue. Ultra-high performance liquid chromatography-triple quadrupole tandem mass spectrometry (UHPLC-QqQ-MS/MS) in conjunction with ultra-ionic liquid dispersive liquid-liquid microextraction (UA-MIL-DLLME) were used to extract NTs for analysis.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Revolutionizing LC-MS with Next-Gen Separation for Cyclic Peptide Analysis
February 17th 2025Cyclic peptides, known for their stability and high specificity, are promising therapeutic agents in the fight against cancer, infections, and autoimmune diseases. However, developing effective cyclic peptides presents numerous challenges, including poor pharmacokinetics, efficacy, and toxicity. Traditional methods like liquid chromatography tandem-mass spectrometry (LC-MS/MS) often struggle with resolving isomeric linear peptide metabolites, posing significant risks in safety, efficacy, and regulatory approval. In this paper, Komal Kedia, PhD, will share how she leveraged MOBIE’s high-resolution ion mobility-mass spectrometry (IM-MS) system to achieve a 72% reduction in run times, 200% greater resolving power, and enhanced accuracy in identifying “soft spots” prone to enzymatic degradation.